アデノ随伴ウイルスベクターの世界市場レポート 2025年

アデノ随伴ウイルスベクター市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6％で60億8,000万米ドルに成長します。予測期間の成長は、治療用途の拡大、遺伝性疾患や神経疾患の有病率の増加、規制当局の承認と支援、生産コストの削減などに起因すると考えられます。予測期間の主な動向としては、遺伝子治療の進歩、技術革新、拡張可能な製造プロセス、共同研究・投資、技術進歩などが挙げられます。

アデノ随伴ウイルスベクター市場は、遺伝性疾患の有病率の増加により成長する見込みです。遺伝性疾患は個人のDNAの異常から発生し、身体的または発達上の問題を引き起こします。診断技術の向上、意識の向上、生殖年齢の上昇、環境の影響、遺伝的ドリフトなどの要因が、遺伝性疾患の有病率上昇に寄与しています。アデノ随伴ウイルスベクターは、筋ジストロフィーや嚢胞性線維症などの疾患を治療する可能性のある、標的細胞に修正遺伝子を送り込むことにより、これらの疾患に対する遺伝子治療において重要な役割を果たしています。例えば、世界保健機関（WHO）が2023年2月に報告したところによると、先天性疾患による生後28日以内の乳児の死亡数は世界で年間約24万人、さらに生後1ヶ月から5歳までの小児の死亡数は17万人であり、アデノ随伴ウイルスベクター市場の原動力を浮き彫りにしています。

アデノ随伴ウイルスベクター市場の主要プレーヤーは、競争力強化のため、複製キャプシドプラスミドの既製品の入手可能性を重視しています。アデノ随伴ウイルス（AAV）ベクター生産のための遺伝子治療で広く使用されているRep/Capプラスミドは、分子生物学研究の要求に応える複数の商業サプライヤーから容易に入手可能です。例えば、Charles River Laboratories International Inc.は、2024年1月に既製の複製-キャプシドプラスミドシリーズを導入し、AAVベースの遺伝子治療イニシアチブを効率化しました。この製品ポートフォリオの拡大は、既存のレンチウイルスパッケージングとAAVヘルパープラスミドを補完するもので、製造の手間を最大66％削減します。これらのすぐに使用できるプラスミドは、CMCガイドラインに準拠し、INDや臨床試験申請（CTA）の提出を容易にする分析証明書（COA）を添付した、詳細な文書化されたバッチ生産が行われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アデノ随伴ウイルスベクターPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアデノ随伴ウイルスベクター市場：成長率分析
• 世界のアデノ随伴ウイルスベクター市場の実績：規模と成長, 2019-2024
• 世界のアデノ随伴ウイルスベクター市場の予測：規模と成長, 2024-2029, 2034F
• 世界アデノ随伴ウイルスベクター総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアデノ随伴ウイルスベクター市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子増強
• 免疫療法
• その他の治療法
• 世界のアデノ随伴ウイルスベクター市場使用される遺伝子送達方法の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生体外
• In vivo
• 世界のアデノ随伴ウイルスベクター市場対象治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝性疾患
• 血液疾患
• 感染症
• 代謝障害
• 眼疾患
• 筋肉障害
• 神経疾患
• その他のターゲット治療領域
• 世界のアデノ随伴ウイルスベクター市場事業規模別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• 臨床
• 商業用
• 世界のアデノ随伴ウイルスベクター市場：応用分野別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• 細胞療法
• ワクチン
• 世界のアデノ随伴ウイルスベクター市場遺伝子増強のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝性遺伝疾患
• 筋ジストロフィー
• 嚢胞性線維症
• 血友病
• 世界のアデノ随伴ウイルスベクター市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん免疫療法
• ウイルス感染症免疫療法
• 自己免疫疾患免疫療法
• 世界のアデノ随伴ウイルスベクター市場、その他の治療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子編集
• RNA療法
• 抗ウイルス療法

第7章 地域別・国別分析

• 世界のアデノ随伴ウイルスベクター市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアデノ随伴ウイルスベクター市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アデノ随伴ウイルスベクター市場：競合情勢
• アデノ随伴ウイルスベクター市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sarepta Therapeutics Inc.
• PTC Therapeutics
• Ultragenyx Pharmaceutical
• Amicus Therapeutics Inc.
• Oxford Biomedica
• Asklepios BioPharmaceutical Inc.
• uniQure biopharma B.V.
• Spark Therapeutics Inc.
• Akouos inc.
• Adverum Biotechnologies Inc.
• Passage Bio Inc.
• AVROBIO Inc
• MeiraGTx Holdings plc
• GenSight Biologics S.A.
• Freeline Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アデノ随伴ウイルスベクター市場2029：新たな機会を提供する国
• アデノ随伴ウイルスベクター市場2029：新たな機会を提供するセグメント
• アデノ随伴ウイルスベクター市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses extensively used in gene therapy to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and various diseases. Their safety profile and efficient infection of both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.

The main types of AAV therapy are gene augmentation, immunotherapy, and others. Gene augmentation involves introducing a functional gene to replace or supplement a defective or missing gene in a patient's cells. This therapy can be delivered through ex vivo or in vivo methods, targeting therapeutic areas such as genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, neurological disorders, and more. The scale of operation ranges from preclinical and clinical stages to commercial applications, applied in gene therapy, cell therapy, and vaccines.

The adeno-associated viral vectors market research report is one of a series of new reports from The Business Research Company that provides adeno-associated viral vectors market statistics, including adeno-associated viral vectors industry global market size, regional shares, competitors with a adeno-associated viral vectors market share, detailed adeno-associated viral vectors market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated viral vectors industry. This adeno-associated viral vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.69 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to vaccine development, increased funding and investment, academic and industrial collaborations, expansion of clinical trials, and public awareness and advocacy.

The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expanding therapeutic applications, increasing the prevalence of genetic disorders, and neurological disorders, regulatory approvals and support, and cost reductions in production. Major trends in the forecast period include gene therapy advancements, technological innovations, scalable manufacturing processes, collaborations and investments, and technological advancements.

The adeno-associated viral vectors market is poised for growth due to the increasing prevalence of genetic disorders. Genetic disorders arise from abnormalities in an individual's DNA, leading to physical or developmental issues. Factors such as improved diagnostic techniques, greater awareness, advanced reproductive age, environmental influences, and genetic drift contribute to the rising prevalence of genetic disorders. Adeno-associated viral vectors play a crucial role in gene therapy for these disorders by delivering corrective genes into target cells, potentially treating conditions such as muscular dystrophy or cystic fibrosis. For example, the World Health Organization (WHO) reported in February 2023 that congenital diseases caused approximately 240,000 infant deaths globally within 28 days of birth annually, with an additional 170,000 deaths in children aged 1 month to 5 years, highlighting the driving force behind the adeno-associated viral vectors market.

Key players in the adeno-associated viral vectors market are emphasizing off-the-shelf availability of replication-capsid plasmids to enhance their competitiveness. Rep/Cap plasmids, widely used in gene therapy for adeno-associated virus (AAV) vector production, are readily accessible from multiple commercial suppliers catering to molecular biology research requirements. For instance, Charles River Laboratories International Inc. introduced an off-the-shelf replication-capsid plasmid range in January 2024, streamlining AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, reducing manufacturing efforts by up to 66%. These ready-to-use plasmids undergo batch production with detailed documentation, complying with CMC guidelines and accompanied by Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.

In May 2024, Merck KGaA, a Germany-based company specializing in pharmaceuticals, biotechnology, and chemical materials, acquired Mirus Bio LLC for $600 million. This acquisition allows Merck KGaA to enhance its life sciences capabilities by incorporating Mirus Bio's advanced RNA-based research and therapeutic technologies. As a result, Merck KGaA strengthens its position in the expanding genetic engineering and biotechnology markets, further advancing its commitment to developing innovative biopharmaceutical products. Mirus Bio LLC, a US-based company, specializes in adeno-associated viral (AAV) vectors and gene delivery technologies.

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

North America was the largest region in the adeno-associated viral vectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adeno-associated viral vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adeno-associated viral vectors market consists of sales of recombinant adeno-associated viral vectors (AAV), serotype-specific adeno-associated viral vectors (AAV), and custom adeno-associated viral vectors (AAV). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adeno-Associated Viral Vectors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adeno-associated viral vectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adeno-associated viral vectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adeno-associated viral vectors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Therapy: Gene Augmentation; Immunotherapy; Other Type Of Therapies
• 2) By Type Of Gene Delivery Method Used: Ex Vivo; In Vivo
• 3) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Areas
• 4) By Scale Of Operation: Preclinical; Clinical; Commercial
• 5) By Application Area: Gene Therapy; Cell Therapy; Vaccines
• Subsegments:
• 1) By Gene Augmentation: Inherited Genetic Disorders; Muscular Dystrophy; Cystic Fibrosis; Hemophilia
• 2) By Immunotherapy: Cancer Immunotherapy; Viral Infections Immunotherapy; Autoimmune Diseases Immunotherapy
• 3) By Other Types Of Therapies: Gene Editing; RNA Therapy; Antiviral Therapy
• Companies Mentioned: Pfizer Inc.; Astellas Pharma; Biogen Inc.; Charles River Laboratories International Inc.; BioMarin Pharmaceutical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adeno-Associated Viral Vectors Market Characteristics

3. Adeno-Associated Viral Vectors Market Trends And Strategies

4. Adeno-Associated Viral Vectors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Adeno-Associated Viral Vectors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adeno-Associated Viral Vectors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adeno-Associated Viral Vectors Market Growth Rate Analysis
• 5.4. Global Adeno-Associated Viral Vectors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adeno-Associated Viral Vectors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adeno-Associated Viral Vectors Total Addressable Market (TAM)

6. Adeno-Associated Viral Vectors Market Segmentation

• 6.1. Global Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Augmentation
• Immunotherapy
• Other Type Of Therapies
• 6.2. Global Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ex Vivo
• In Vivo
• 6.3. Global Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Disorders
• Hematological Disorders
• Infectious Diseases
• Metabolic Disorders
• Ophthalmic Disorders
• Muscle Disorders
• Neurological Disorders
• Other Target Therapeutic Areas
• 6.4. Global Adeno-Associated Viral Vectors Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.5. Global Adeno-Associated Viral Vectors Market, Segmentation By Application Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Cell Therapy
• Vaccines
• 6.6. Global Adeno-Associated Viral Vectors Market, Sub-Segmentation Of Gene Augmentation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inherited Genetic Disorders
• Muscular Dystrophy
• Cystic Fibrosis
• Hemophilia
• 6.7. Global Adeno-Associated Viral Vectors Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Immunotherapy
• Viral Infections Immunotherapy
• Autoimmune Diseases Immunotherapy
• 6.8. Global Adeno-Associated Viral Vectors Market, Sub-Segmentation Of Other Types Of Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Editing
• RNA Therapy
• Antiviral Therapy

7. Adeno-Associated Viral Vectors Market Regional And Country Analysis

• 7.1. Global Adeno-Associated Viral Vectors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adeno-Associated Viral Vectors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adeno-Associated Viral Vectors Market

• 8.1. Asia-Pacific Adeno-Associated Viral Vectors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adeno-Associated Viral Vectors Market

• 9.1. China Adeno-Associated Viral Vectors Market Overview
• 9.2. China Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adeno-Associated Viral Vectors Market

• 10.1. India Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adeno-Associated Viral Vectors Market

• 11.1. Japan Adeno-Associated Viral Vectors Market Overview
• 11.2. Japan Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adeno-Associated Viral Vectors Market

• 12.1. Australia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adeno-Associated Viral Vectors Market

• 13.1. Indonesia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adeno-Associated Viral Vectors Market

• 14.1. South Korea Adeno-Associated Viral Vectors Market Overview
• 14.2. South Korea Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adeno-Associated Viral Vectors Market

• 15.1. Western Europe Adeno-Associated Viral Vectors Market Overview
• 15.2. Western Europe Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adeno-Associated Viral Vectors Market

• 16.1. UK Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adeno-Associated Viral Vectors Market

• 17.1. Germany Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adeno-Associated Viral Vectors Market

• 18.1. France Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adeno-Associated Viral Vectors Market

• 19.1. Italy Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adeno-Associated Viral Vectors Market

• 20.1. Spain Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adeno-Associated Viral Vectors Market

• 21.1. Eastern Europe Adeno-Associated Viral Vectors Market Overview
• 21.2. Eastern Europe Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adeno-Associated Viral Vectors Market

• 22.1. Russia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adeno-Associated Viral Vectors Market

• 23.1. North America Adeno-Associated Viral Vectors Market Overview
• 23.2. North America Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adeno-Associated Viral Vectors Market

• 24.1. USA Adeno-Associated Viral Vectors Market Overview
• 24.2. USA Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adeno-Associated Viral Vectors Market

• 25.1. Canada Adeno-Associated Viral Vectors Market Overview
• 25.2. Canada Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adeno-Associated Viral Vectors Market

• 26.1. South America Adeno-Associated Viral Vectors Market Overview
• 26.2. South America Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adeno-Associated Viral Vectors Market

• 27.1. Brazil Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adeno-Associated Viral Vectors Market

• 28.1. Middle East Adeno-Associated Viral Vectors Market Overview
• 28.2. Middle East Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adeno-Associated Viral Vectors Market

• 29.1. Africa Adeno-Associated Viral Vectors Market Overview
• 29.2. Africa Adeno-Associated Viral Vectors Market, Segmentation By Type Of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adeno-Associated Viral Vectors Market, Segmentation By Type Of Gene Delivery Method Used, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adeno-Associated Viral Vectors Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adeno-Associated Viral Vectors Market Competitive Landscape And Company Profiles

• 30.1. Adeno-Associated Viral Vectors Market Competitive Landscape
• 30.2. Adeno-Associated Viral Vectors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Adeno-Associated Viral Vectors Market Other Major And Innovative Companies

• 31.1. Sarepta Therapeutics Inc.
• 31.2. PTC Therapeutics
• 31.3. Ultragenyx Pharmaceutical
• 31.4. Amicus Therapeutics Inc.
• 31.5. Oxford Biomedica
• 31.6. Asklepios BioPharmaceutical Inc.
• 31.7. uniQure biopharma B.V.
• 31.8. Spark Therapeutics Inc.
• 31.9. Akouos inc.
• 31.10. Adverum Biotechnologies Inc.
• 31.11. Passage Bio Inc.
• 31.12. AVROBIO Inc
• 31.13. MeiraGTx Holdings plc
• 31.14. GenSight Biologics S.A.
• 31.15. Freeline Therapeutics

32. Global Adeno-Associated Viral Vectors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adeno-Associated Viral Vectors Market

34. Recent Developments In The Adeno-Associated Viral Vectors Market

35. Adeno-Associated Viral Vectors Market High Potential Countries, Segments and Strategies

• 35.1 Adeno-Associated Viral Vectors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adeno-Associated Viral Vectors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adeno-Associated Viral Vectors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer